Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BB 2827

Drug Profile

BB 2827

Latest Information Update: 09 Apr 2009

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator British Biotech
  • Developer British Biotech; Merck Serono
  • Class Antirheumatics
  • Mechanism of Action Matrix metalloproteinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Periodontal disorders; Rheumatoid arthritis

Most Recent Events

  • 27 Jul 2001 Discontinued-I for Rheumatoid arthritis in Europe (PO)
  • 26 Jun 2001 Investigation in Periodontal disorders in Europe (PO)
  • 31 Oct 2000 Serono has an option to obtain exclusive rights to BB 2827
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top